SOURCE: Medpace


September 06, 2012 06:00 ET

Medpace Completes Relocation of Medpace Reference Laboratories (MRL) to Site of New Corporate Campus, Doubling Medpace Central Laboratory Capacity

CINCINNATI, OH--(Marketwire - Sep 6, 2012) -   Medpace, Inc. today announced the opening of Medpace Reference Laboratories (MRL) at 5365 Medpace Way, Cincinnati, OH. The existing MRL facility in Norwood will close at the conclusion of the move.

Medpace's new central lab facility is designed with 50,000 square feet of customized space, featuring state-of-the-art instrumentation and dedicated project teams. MRL will maintain existing Medpace methodology and operating procedures across their four global labs. The new facility is twice the size of the former MRL footprint, allowing for expanded support of global studies that Medpace conducts on behalf of Sponsors. 

MRL has industry-leading quality assurance and accreditation including CDC Part III (Gold standard) lipid standardization, NGSP (level I) certification and CAP accreditation. MRL uses Clintrak®, Medpace's proprietary decision support software for managing trial specifics in real time and providing Sponsor direct access to their data.

"MRL teams have always provided operational excellence and gold standard methods in all therapeutic areas we support," said Dr. August Troendle, President, Medpace. "We have now increased the scale and infrastructure of the labs, ensuring that Medpace can smoothly expand our support for new and esoteric biomarkers that our Sponsors would like available." 

Medpace Reference Laboratories join Medpace global headquarters, Medpace Clinical Research Organization (CRO), and Medpace Clinical Pharmacology Unit (MCPU) at the new Medpace Way Campus.


Medpace Reference Laboratories (MRL) is a leader in providing customized, full service, central laboratory services to the pharmaceutical and biotech clinical development industries. MRL operates regional central laboratories that cover clinical trial needs across the globe: Cincinnati, Ohio; Leuven, Belgium; Beijing, China; and Mumbai, India. MRL provides state-of-the-art facilities, instrumentation, and methodology (identical in all Medpace labs) with global coverage. MRL provides industry-leading quality assurance and accreditation including CDC Part III (Gold standard) lipid standardization, NGSP (level I) certification, and CAP accreditation.


Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. 

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1200 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at